CDSCO Approves Wockhardt’s Breakthrough Antibiotic ZAYNICH® for Complicated Urinary Tract Infections
Wockhardt has received marketing authorization from India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for its breakthrough antibiotic ZAYNICH® (Zidebactam/Cefepime). The approval marks a significant milestone for India’s fight against antimicrobial resistance, especially in difficult-to-treat Gram-negative bacterial infections.





















